Capricor Therapeutics Enters Acquisition Term Sheet

Ticker: CAPR · Form: 8-K · Filed: Apr 29, 2024 · CIK: 1133869

Capricor Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCapricor Therapeutics, Inc. (CAPR)
Form Type8-K
Filed DateApr 29, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: acquisition, merger, term-sheet

Related Tickers: CAPR

TL;DR

CAPR signs term sheet for acquisition, deal details TBD.

AI Summary

Capricor Therapeutics, Inc. announced on April 29, 2024, that it has entered into a binding term sheet with an unaffiliated third party for a potential acquisition. The term sheet outlines the key terms and conditions for the acquisition, subject to definitive agreement and customary closing conditions. Further details regarding the transaction are expected to be disclosed upon execution of the definitive agreement.

Why It Matters

This potential acquisition could significantly alter Capricor's corporate structure and future strategic direction, impacting its ongoing drug development programs and shareholder value.

Risk Assessment

Risk Level: medium — The announcement of a term sheet indicates a significant potential change for the company, but the deal is not yet finalized, introducing uncertainty.

Key Players & Entities

  • Capricor Therapeutics, Inc. (company) — Registrant
  • April 29, 2024 (date) — Date of Report

FAQ

What is the nature of the binding term sheet Capricor Therapeutics entered into?

Capricor Therapeutics entered into a binding term sheet with an unaffiliated third party for a potential acquisition of the company.

When was this term sheet announced?

The term sheet was announced on April 29, 2024.

Are there specific financial terms disclosed in the term sheet?

The provided text does not disclose specific financial terms of the term sheet; it only states that the term sheet outlines key terms and conditions.

What are the conditions for the acquisition to be completed?

The acquisition is subject to the execution of a definitive agreement and customary closing conditions.

When can more details about the transaction be expected?

Further details are expected to be disclosed upon the execution of the definitive agreement.

Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-04-29 09:25:17

Key Financial Figures

  • $0.001 — h Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital M

Filing Documents

01

Item 7.01 Regulation FD Disclosure. Attached hereto as Exhibit 99.1 to this Current Report on Form 8-K is a slide presentation that the Company reviewed in conjunction with its CAP-1002 Duchenne muscular dystrophy ("DMD") program update call and webcast on April 29, 2024. The information under Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any of the Company's filings under the Exchange Act, unless expressly set forth as being incorporated by reference into such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Capricor Therapeutics, Inc. slide presentation, dated April 29, 2024. 104 Cover Page Interactive Data File (formatted as inline XBRL). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CAPRICOR THERAPEUTICS, INC. Date: April 29, 2024 By: /s/ Linda Marbn, Ph.D. Linda Marbn, Ph.D. Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.